1: Final Report on the Safety Assessment of Hydroxyethylcellulose,Hydroxypropylcellulose,Methylcellulose,Hydroxypropyl Methylcellulose,and Cellulose Gum
Free accessResearch articleFirst published online May, 1986
1: Final Report on the Safety Assessment of Hydroxyethylcellulose,Hydroxypropylcellulose,Methylcellulose,Hydroxypropyl Methylcellulose,and Cellulose Gum
Hydroxyethylcellulose, Hydroxypropylcellulose, Methylcellulose, Hydroxypropyl Methylcellulose, and Cellulose Gum are modified cellulose polymers that are used in cosmetic products at concentrations up to 10%. The cellulose derivatives pass essentially unchanged through the gastrointestinal tract following oral administration. They are practically nontoxic when administered by inhalation or by oral, intraperitoneal, subcutaneous, or dermal routes. Subchronic and chronic oral studies indicate that the cellulose derivatives are nontoxic when administered to laboratory animals. No significant teratogenic or reproductive effects have been demonstrated. Ocular and dermal irritation studies show that the cellulose derivatives are, at most, minimally irritating to rabbit eyes and nonirritating to slightly irritating to rabbit skin when tested at concentrations up to 100%. No mutagenic activity of theseingredients was demonstrated. The cellulose derivatives at concentrations up to 100% were nonirritating to mildly irritating, nonsensitizing, and nonphotosensitizing when evaluated in clinical studies. It is concluded that theingredients reviewed are safe as cosmeticingredients in the present practices of use and concentration.
References
1.
1. INFORMATICS. (December 1972). GRAS foodingredients. Cellulose and derivatives. For the FDA, National Technical Information Service (NTIS) PB No. 221–28.
2.
2. FEDERATION OF AMERICAN SOCIETIES FOR EXPERIMENTAL BIOLOGY (FASEB). LIFE SCIENCES RESEARCH OFFICE. (November 1974). Evaluation of the health aspects of Cellulose and certain Cellulose derivatives as foodingredients. For the FDA, Contract No. FDA 72–85. NTIS PB No. 274–667.
3.
3. COSMETIC, TOILETRY AND FRAGRANCE ASSOCIATION (CTFA). (October 21, 1982). CosmeticIngredient Chemical Description, Hydroxyethylcellulose (2–20–100).
4.
4. CTFA. (October 21, 1982). CosmeticIngredient Chemical Description, Hydroxypropylcellulose (2–20–102).
5.
5. CTFA. (October 21, 1982). CosmeticIngredient Chemical Description, Methylcellulose (2–20–104).
8. Hake, C.L., and Rowe, V.K. (1963). Cellulose ethers. In: Industrial Hygiene and Toxicology, 2nd ed. F.A. Patty (ed.). New York: Wiley, pp. 1709–18.
9.
9. Guillot, J.P., Giauffret, J.Y., Martini, M.C., Gonnet, J.F., and Soule, G. (1980–1981). Safety evaluation of cosmetic raw materials: Results obtained with 160 samples from various origins. Riv. Ital. E.P.P.O.S.62(6), 282–92, 1980; 63(1), 39–45, 1981; 63(2), 109–18, 1981.
10.
10. Rufe, R.G. (March 1975). Cellulose polymers in cosmetics and toiletries. Cosmet. Perfum.90, 93–100.
11.
11. Holly, F.J. (1978). Surface chemical evaluation of artificial tears and theiringredients. I. Interfacial activity at equilibrium. Contact Intraocul. Lens Med. J.4(2), 14–26, 28–31.
12.
12. Holly, F.J. (1978). Surface chemical evaluation of artificial tears and theiringredients. II. Interaction with a superficial lipid layer. Contact Intraocul. Lens Med. J.4(3), 52–9, 63–5.
13.
13. Savage, A.B., Young, A.E., and Maasberg, A.T. (1954–1955). Derivatives of Cellulose-Ethers. In: Cellulose and Cellulose Derivatives, 2nd ed.Ott (ed.). New York: Wiley-Interscience, pp. 882–954.
14.
14. Haugen, P., Tung, M.A., and Runikis, J.O. (1978). Steady shear flow properties, rheological reproducibility and stability of aqueous Hydroxyethylcellulose dispersions. Can. J. Pharm. Sci.13(1), 4–7.
16. Kostolowska, M., Krowczynski, L., and Salamon, M. (1981). Compatibility of viscosity-increasing agents with active substances in eye drops. Farm. Pol.37(4), 209–12.
17.
17. Miyata, N., Sakata, I., and Senju, R. (1975). Effects of the properties of trunk polymers on the flocculating action of graft copolymers. Bull. Chem. Soc. Jpn.48(11), 3367–71.
18.
18. Bustos, D., and Cid, E. (1975). Biopharmaceutical study of p-Aminosalicylic acid tablets. Farmaco. Ed. Prat.30(8), 388–97.
19.
19. Voight, R., Guide, C., and Fechner, C. (1978). Interactions between macromolecular adjuvants and drugs. Part 14. Effects of drug-adjuvant binding, recognized by Equil. Dialysis, on release behavior in hydrogels. Pharmazie33(11), 732–5.
20.
20. Klose, R.E., and Glicksman, M. (1972). Gums. In: CRC Handbook of Food Additives, 2nd ed.T.E. Furia (ed.). Cleveland, OH: CRC Press, Vol. 1, pp. 295–359.
21.
21. Eros, I., and Csordas, M.A. (1979). Preparation and properties of Hydroxyethylcellulose mucilage. III. Study of the stability. Gyogyszereszet23(12), 450–3.
22.
22. Desmarais, A.J. (1973). In: Industrial Gums, 2nd ed.R.L. Whistler (ed.). New York: Academic Press, pp. 649–72.
23.
23. Estrin, N.F., Haynes, C.R., and Whelan, J.M. (eds.). (1982). CTFA Specifications/Spectra. Washington, DC: Cosmetic, Toiletry and Fragrance Association.
24.
24. Greminger, G.K. Jr., and Savage, A.B. (1973). Methylcellulose and its derivatives. In: Industrial Gums, 2nd ed.R.L. Whistler (ed.). New York: Academic Press, pp. 619–47.
25.
25. Windholz, M. (ed.). (1983). The Merck Index, 10th ed.Rahway, NJ: Merck and Co.
26.
26. Batdorf, J.B. (1959). Sodium carboxymethylcellulose. In: Industrial Gums. R.L. Whistler (ed.). New York: Academic Press, pp. 643–74.
27.
27. Food Chemicals Codex (Fcc) (1981). Food and Nutrition Board, National Research Council. Washington, DC: National Academy Press.
28.
28. Raftery, M.M. (1975). Explosibility tests for industrial dusts. Fire Res. Tech. Pap. 21.
29.
29. The United States Pharmacopeia (Usp) (1979). 20th revision. Official from July 1, 1980. Rockville, MD: United States Pharmacopeial Convention.
30.
30. Food And Drug Administration (Fda) (Dec. 1981). Product formulation data. Computer printout. Washington, DC.
36. STANFORD RESEARCH INSTITUTE (SRI). (1982). Toxicology data bank file. Hydroxyethylcellulose, use.
37.
37. Yamazaki, H., Katagiri, K., and Tsuda, H. (June 5, 1975). Electrolytic treatment of waste containing organic nitrogen. Jpn. Kokai Patent No. 75 66958 (Tomoegawa Paper Mfg. Co., Ltd.).
38.
38. Miyata, N., and Sakata, I. (1979). Flocculating action of cellulose-dimethylaminoethyl methacrylateacrylamide graft copolymers. Sen'i Gakkaishi35(7), T283–8.
39.
39. Johansen, C. (1972). Spray additives for insecticidal selectivity to injurious vs. beneficial insects. Environ. Entomol.1(1), 51–4.
40.
40. Braley, G.K. (1980). Several remedies for the treatment of spillages of liquid hazardous chemicals. Control Hazard. Mater. Spills., Proc. Natl. Conf. 103–8.
41.
41. Lerk, C.F., Lagas, M., Fell, J.T., and Nauta, P. (July 1978). Effect of hydrophilization of hydrophobic drugs on release rate from capsules. J. Pharm. Sci.67, 935–9.
42.
42. Delonca, H., Joachim, J., and Mattha, A. (May-June 1978). Influence of temperature on disintegration and dissolution time of tablets with a cellulose component as a binder. J. Pharm. Belg.33, 171–8.
43.
43. Szabo-Revesz, P., Keresztes, A., and Selmeczi, B. (1978). Effects of Cellulose ethers on the properties of furosemide tablets. Pharmazie33(5), 287–9.
44.
44. Moldenhauer, H., Loh, H.J., and Kala, H. (1978). Optimal use of celluloses as adjuvants in tableting. Part 3. Characteristics of the use of adjuvant mixtures with the aid of regression models. Pharmazie33(6), 349–53.
46. Holly, F.J. (1979). Surface chemical evaluation of artificial tears and theiringredients. III. Dynamic properties. Contact Intraocul. Lens Med. J.5(1), 21–33.
47.
47. Capella, J.A., and Schaefer, I.M. (January 1974). Comparison of ophthalmic vehicles using fluorescein uptake technique. Eye Ear Nose Throat Mon.53, 54–7.
48.
48. Porst, H., and Kny, L. (1980). Stability of neostigmine in eye drops. Part 1: Analysis and long term examination. Zentralbl. Pharm. Pharmakother. Laboratoriumsdiagn.119(7), 707–20.
49.
49. Keseru, P., Gyorffy, L., and Csontos, A. (1972). Some problems of ophthalmic solutions necessary for those using contact lenses. Part I. Physicochemical and microbiological aspects. Gyogyszereszet16(9), 333–6.
50.
50. Takebe, T., and Yamazaki, T. (August 26, 1976). Water-dispersible absorption medium for blood and similar materials. Ger. Offen. Patent No. 2605907 (Eisai Co., Ltd.).
51.
51. Groves, R.E. (October 29, 1980). Composition for the treatment of cold sores and other infections caused by microorganisms. S. African Patent No. 80 00551 10/29/80 (Unilever South Africa [Pty.] Ltd.).
52.
52. Nagai, T., Machida, Y., Suzuki, Y., and Ikura, H. (October 7, 1980). Preparation for administration to the mucosa of the oral or nasal cavity. U.S. Patent No. 4226848 (Teijin Ltd.).
54. Sherman, K.N., and Jacobson, A. (February 24, 1981). Antifertility composition. U.S. Patent No. 4252787 (Cambridge Research and Development Group).
55.
55. Retzke, U., Furtig, W., and Schwarz, R. (1976). Complex treatment of postirradiation injuries of the urinary bladder. Ginekol Pol.47(3), 327–37.
56.
56. Barczynska, J. (1973). Pharmacological properties of alpha-phenyltetrahydrofuranone-2-gamma-carboxylic acid and its derivatives. Arch. Immunol. Ther. Exp.21(2), 309–27.
57.
57. FDA. (May 6, 1980). Establishment of a monograph and proposed rulemaking on ophthalmic drug products for over-the-counter human use. Fed. Reg.45(89), 30005–6, 30021, 30039–40.
58.
58. FDA. (December 12, 1980). Establishment of a monograph and proposed rulemaking on vaginal contraceptive drug products for over-the-counter human use. Fed. Reg.45(241), 82016–7.
59.
59. Fey, F., and Ring, G. (1976). A modified screening model for potential cancerostatics by intravenous application of L1210 ascites cells. 7705 Arch. Geschwulstforsh.46(6), 461–70.
60.
60. Jungstand, W., Gutsche, W., and Wohlrabe, K. (1972). Cytostatic effect of 1-methyl-2-p-[bis-(beta)-chloroethyl)amino]phenyliminomethyl quin-olinium chloride (IMET 3106) against the growth of transplantable tumors. Arch. Geschwulstforsch.40(1), 35–9.
61.
61. Jungstand, W., Gutsche, W., Wohlrabe, K., and Schulze, W. (1979). Cancerostatic effect of some azomethines of fluorenone on leukemia L1210. Arch. Geschwulstforsh.49(1), 15–7.
63. Davis, T.A. (1978). Activated carbon fibers for artificial kidney devices report: ISS SORI-EAS-78–311, AK-6–72–2208-F. NTIS Order No. PB-288494, 61 pp.
64.
64. Holland, F.F., Donnaud, A., Gidden, H.E., and Klein, E. (1977). Methods of measurement of mass transfer rates and capacities of hemoperfusion cartridges. Trans. Am. Soc. Artif. Intern. Organs23, 573–82.
65.
65. Ben-Hur, N., and Appelbaum, J. (1973). Biochemistry, histopathology and treatment of phosphorus burns: An experimental study. Isr. J. Med. Sci.9(1), 40–8.
66.
66. Greene, H.L., Chalasani, V.R., and Nokes, R.F. (1973). Effects of drag reducing polymer on hemolysis rates during extracorporeal pumping. Proc. Annu. Conf. Eng. Med. Biol.15, 414.
67.
67. Greene, H.L., and Madan, S.R. (1975). The role of fluid viscoelasticity during in vitro destruction of erythrocytes. Biorheology12(6), 377–82.
68.
68. Takebe, T., Aitaku, S., Yamazaki, T., and Takagi, M. (October 21, 1977). Absorbent for blood and other physiological fluid dispersable in water. Jpn. Kokai Patent No. 77125481 (Eisai Co., Ltd.).
73. LION CORPORATION. (February 23, 1981). Removal of nicotine tar from teeth. Jpn. Kokai Tokkyo Patent No. 81 18912.
74.
74. Vezin, J.C., and Hascoet, P. (September 16, 1977). Complexes of poly(vinylpyrrolidone) and active principles used in dental therapeutics. Fr. Demande Patent No. 2341320 (Fabre, Pierre, S. A.).
75.
75. Caughman, H.D., and Brown, W.E. (November 23, 1976). Aqueous compositions to aid in the prevention of bovine mastitis. U.S. Patent No. 3993777 (Bio-Lab, Inc.).
76.
76. Andrews, J.F., Mullin, T.A., and Senkus, R. (July 13, 1978). Agent for preventing mastitis in milk-producing animals. Ger. Offen. Patent No. 2800896 (Minnesota Mining and Mfg. Co.).
77.
77. Child, J.J., Eveleigh, D.E., and Sieben, A.S. (January 1973). Determination of cellulase activity using hydroxyethylcellulose as substrate. Can. J. Biochem.51(1), 39–43.
78.
78. Scharple, S., Lauwers, A., Cooreman, W., and Sierens, W. (Dec. 14, 1973). Viscosimetric assay of fungi celluloses with hydroxyethylcelluloses as substrate. Arch. Int. Physiol. Biochim.81(5), 982.
79.
79. Beck, L.R., and Davis, T.A. (February 24, 1981). Hemoperfusion device for specific modification or removal of components of whole blood. U.S. Patent No. 4252653 (Stolle Research and Development Corp.).
80.
80. Kerry, P.J. (November 1976). The isolation of ovine lymphocytes and granulocytes from whole blood using Hydroxyethylcellulose. Res. Vet. Sci.21(3), 356–7.
81.
81. Meulenbelt, F., and Vos, T. (1978). Barium suspensions for combined double-contrast and single (positive) radiography. Pharm. Weekbl.113(22), 528–32.
82.
82. Patel, V.J. (1978). Tantalum in the diagnosis of ureter and renal pelvis tumors. A preliminary report. Urologe [A]17(3), 150–4.
83.
83. Queuille, A., and Herbemont, F. (December 15, 1977). X-ray contrast agent based on barium sulfate. Ger. Offen. Patent No. 2723878 (Roussel-UCLAF).
85. CODE OF FEDERAL REGULATIONS (CFR). (1982). Title 21, Part 175.105. Washington, DC.
86.
86. CFR. (1982). Title 21, Part 175.300. Washington, DC.
87.
87. CFR. (1982). Title 21, Part 177.1200. Washington, DC.
88.
88. CFR. (1982). Title 21, Part 177.1400. Washington, DC.
89.
89. Fell, J.T., Calvert, R.T., and Riley-Bentham, P. (August 1978). Bioavailability of griseofulvin from a novel capsule formulation. J. Pharm. Pharmacol.30, 479–82.
90.
90. Machida, Y., Masuda, H., Fujiyama, N., Ito, S., Iwata, M., and Nagai, T. (1979). Preparation and Phase II clinical examination of topical dosage form for treatment of carcinoma colli containing bleomycin with hydroxypropyl cellulose. Chem. Pharm. Bull. (Tokyo)27(1), 93–100.
91.
91. Katz, I.M. (February 10, 1977). Hydroxypropyl cellulose-containing preparations for the treatment of keratoconjunctivitis sicca (dry eye syndrome). Ger. Offen. Patent No. 2633988 (Merck and Co.).
92.
92. Sarkar, N. (August 12, 1976). Pharmaceutical capsules from improved heat-gelable Methylcellulose ethers. Ger. Offen. Patent No. 2554164 (Dow Chemical).
93.
93. Suzuki, Y., Ikura, H., Yamashita, G., and Nagai, T. (February 4, 1981). Powdery pharmaceutical composition for application to the nasal mucosa. Eur. Pat. Appl. Patent No. 23359 (Teijin Ltd).
94.
94. TEIJIN LTD. (October 3, 1980). Composition to adhere to the oral or nasal mucous membrane and slowly liberate active substances it contains. Fr. Demande Patent No. 2450610.
95.
95. TEIJIN LTD. (August 12, 1981). Medications for treatment of uterus cancer. Jpn. Kokai Tokkyo Koho Patent No. 81100711.
96.
96. CFR. (1982). Title 21, Part 172.870. Washington, DC.
97.
97. FDA. (June 4, 1974). Antacid products for over-the-counter (OTC) human use. Fed. Reg.39(108), 19874.
98.
98. FDA. (September 5, 1978). Antacid products for over-the-counter human use. Fed. Reg.43(172), 39427–8.
99.
99. Rossoff, I.S. (1974). Handbook of Veterinary Drugs. New York: Springer Publishing Co.
100.
100. CFR. (1982). Title 21, Part 182.1480. Washington, DC.
101.
101. CFR. (1982). Title 21, Part 172.874. Washington, DC.
102.
102. CFR. (1982). Title 21, Part 175.210. Washington, DC.
103.
103. CFR. (1982). Title 21, Part 176.200. Washington, DC.
104.
104. DARCEL CHEMICAL INDUSTRIES. (March 20, 1981). Carboxymethyl cellulose salts for the manufacture of sanitary napkins. Jpn. Kokai Tokkyo Koho Patent No. 81 28755.
105.
105. Checchi, A.A. (1983). OTC DrugIngredient Index and Manual. Washington, DC, pp. 158.0, 158.1, 158A-1.0.
106.
106. CFR. (1982). Title 21, Part 182.1745. Washington, DC.
107.
107. CFR. (1982). Title 21, Part 182.70. Washington, DC.
108.
108. CFR. (1982). Title 21, Part 173.310. Washington, DC.
109.
109. Okada, S., and Fletcher, G.L. (1967). Effects of gamma radiation on deoxyribonuclease I in the presence of high concentrations of second solutes. Radiat. Res.30(4), 667–75.
110.
110. Kitagawa, H., and Saito, H. (1978). General pharmacology of hydroxypropylcellulose of low substitution (L-HPC). Oyo Yakuri16(2), 299–302.
111.
111. Soci, M.M., and Parrott, E.L. (April 1980). Influence of viscosity of absorption from nitrofurantoin suspensions. J. Pharm. Sci.69, 403–6.
112.
112. Marvola, M., Pirjola, J., and Huikari, A. (July 1979). Effect of some viscosity enhancing agents on the intestinal absorption of sulfafurazole in the rat. Int. J. Pharm.3, 13–22.
113.
113. Sekikawa, H., Ito, K., Arita, T., Hori, R., and Nakano, M. (1979). Effects of macromolecular additives and urea on the intestinal absorption of acetaminophen in rats. Chem. Pharm. Bull.27(5), 1106–11.
114.
114. Lerk, C.F., Lagas, M., Lie-A-Huen, L., Broersma, P., and Zuurman, K. (May 1979). In vitro and in vivo availability of hydrophilized phenytoin from capsules. J. Pharm. Sci.68, 634–8.
115.
115. Lagas, M., Lerk, C.F., and Breimer, D.D. (April 25, 1980). Increased gastrointestinal absorption of hexobarbital by hydrophilization. Pharm. Weekbl. Sci. Ed.2, 33–9.
116.
116. Said, S.A., and Al-Shora, H.I. (January 1981). Hypoglycemic activity of oral hypoglycemics with increased hydrophilicity. J. Pharm. Sci.70, 67–70.
117.
117. Nagataki, S., and Sugaya, M. (1978). Methyl cellulose and ointment vehicles: Their effects on ocular pharmacokinetics. Nippon Ganka Gakkai Zasshi82(2), 127–34.
118.
118. Kiyozumi, M., Mishima, M., Noda, S., Miyata, K., Takahashi, Y., Mizunaga, F., Nakagawa, M., and Kojima, S. (1982). Studies on poisonous metals. IX. Effects of dietary fibers on absorption of cadmium in rats. Chem. Pharm. Bull.30(12), 4494–9.
119.
119. Quazi, S., Yokogoshi, H., and Yoshida, A. (1983). Effect of a dietary fiber on hypercholesterolemia induced by dietary PCB or cholesterol in rats. J. Nutr.113(6), 1109–18.
120.
120. Takeda, H., Ebihara, K., Hayashi, Y., and Kiriyama, S. (1979). Influence of dietary fibers on the toxicity of Food Red No. 2 (amaranth) and on the amino toxicities in rats. Nippon Nogei Kagaku Kaishi53(9), 291–7.
121.
121. Barzegar-Jalali, M., and Richards, J.H. (1979). The effects of various suspending agents on the bioavailabilities of aspirin and salicylic acid in the rabbit. Int. J. Pharm.3(2–3), 133–41.
122.
122. Decorti, G., Klugmann, F.B., Mallardi, F., Brovedani, R., Baldini, G., and Baldini, L. (1983). Enhancement of adriamycin toxicity by carboxymethylcellulose in mice. Toxicol. Appl. Pharmacol.71, 288–93.
123.
123. Brooks, R., and Pong, S.F. (1981). Effects of fasting, body weight, methylcellulose and carboxymethylcellulose on hepatic glutathione levels in mice and hamsters. Biochem. Pharmacol.30, 589–94.
124.
124. Koike, T., and Pfieffer, S.E. (1979). Carboxymethyl cellulose stimulation of neurite outgrowth of neuroblastoma cells in culture. Dev. Neurosci.2(4), 177–82.
125.
125. MacRae, S.M., Edelhauser, H.F., Hyndiuk, R.A., Burd, E.M., and Schultz, R.O. (1983). The effects of sodium hyaluronate, chondroitin sulfate, and methylcellulose on the corneal endothelium and intraocular pressure. Am. J. Ophthamol.95(3), 332–41, 1983.
126.
126. Richter, W. (1969). Increased vascular permeability in mice induced by dextran. A comparison with the anaphylactoid reaction in rats. Acta Pharmacol. Toxicol.27(5), 331–48.
127.
127. Mostardi, R.A., Greene, H.L., Nokes, R.F., Thomas, L.C., and Lue, T. (1976). The effect of drag reducing agents on stenotic flow disturbances in dogs. Biorheology13(2), 137–41.
128.
128. Greene, H.L., and Madan, S.R. (September 1974). Proc. GVC/A.I.C.L.E. Joint Meeting, Munich, Germany.
129.
129. Declercq, S.S. (February 1977). The coating agent on the corneal contact lens in electroretinography. Am. J. Ophthalmol.83(2), 267–71.
130.
130. Stang, H.D., and Boggs, D.R. (1977). Effect of methylcellulose injection on murine hematopoiesis. Am. J. Physiol.233, H234–39.
131.
131. Pfrimmer, W., Joyce, R.A., Turner, A.R., and Boggs, D.R. (1978). Kinetics of the development of methylcellulose-induced hepatic hematopoiesis in adult mice. Blood51, 611–22.
132.
132. Fiala, J., and Viktora, L. (1973). Kotazie transplantace bunek krvetvornych organo u hypersplenickychmysi. Cas. Lek. Cesk.112, 694–6.
133.
133. Scheiffarth, F.H., Baenkler, W., and Peter, K.H. (1971). The kinetics of plaque-forming cells in experimental hypersplenism. Acta Haematol.45, 266–71.
134.
134. Palmer, J.G., Eichwald, E.J., Cartwright, G.E., and Wintrobe, M.M. (1953). The experimental production of splenomegaly, anemia and leukopenia in albino rats. Blood8, 72–80.
135.
135. Rowley, D.A., Fitch, F.W., and Bye, I.J. (1962). Anemia produced in the rat by methylcellulose. Arch. Pathol.74, 81–89.
136.
136. Hueper, W.C. (1942). Experimental studies in cardiovascular pathology. IV. Methylcellulose atheromatosis and thesaurosis. Arch. Pathol.33, 1.
137.
137. Kitagawa, H., Saito, H., Yokoshima, T., Nanbo, T., Ushioda, K., Ueda, T., and Oyabu, S. (1976). Absorption, distribution, excretion and metabolism of 14C-Hydroxypropylcellulose of low substitution. Oyo Yakuri12(1), 33–9.
138.
138. CTFA. (November 12, 1968). Submission of unpublished data by CTFA. Distribution study in rats on HPC. (2–20–41).
139.
139. CTFA. (August 22, 1955). Submission of unpublished data by CTFA. Distribution study in rats on CG. (2–20–30).
140.
140. CTFA. (January 9, 1975). Submission of unpublished data by CTFA. Rat acute oral LDso test on HEC. (2–20–45).
141.
141. Smyth, Jr., H.F., Carpenter, C.P., and Weil, C.S. (1947). The chronic toxicity of hydroxyethylcellulose for rats. J. Am. Pharm. Assoc. Sci. Ed.36, 335–6.
142.
142. Kitagawa, H., Tokunaga, T., Ebihara, S., Kawana, H., and Satoh, T. (1970). Acute toxicities of hydroxypropyl cellulose in mice and rats. Oyo Yakuri4(6), 1013–15.
143.
143. Kitagawa, H., Yano, H., Saito, H., and Fukuda, Y. (1976). Acute, subacute and chronic toxicities of hydroxypropylcellulose of low substitution in rats. Oyo Yakuri12(1), 41–66.
144.
144. CTFA. (September 25, 1962). Submission of unpublished data by CTFA. Acute oral rat study on HPC. (2–20–41).
145.
145. STILLMEADOW. (April 13, 1977). Rat acute oral toxicity study on HPC. (2–20–12).
146.
146. CTFA. (May 1978). Submission of unpublished data by CTFA. Acute oral rat study on HPMC. (2–20–87).
147.
147. CTFA. (December 1971). Submission of unpublished data by CTFA. Acute oral rat study on CMC. (2–20–81).
148.
148. CTFA. (August 14, 1970). Submission of unpublished data by CTFA. Acute oral rat study on CG. (2–20–35).
149.
149. CTFA. (November 3, 1945). Submission of unpublished data by CTFA. Acute oral rat study on CG. (2–20–36).
150.
150. CTFA. (November 3, 1945). Submission of unpublished data by CTFA. Acute oral guinea pig study on CG. (2–20–37).
151.
151. CTFA. (February 11, 1980). Submission of unpublished data by CTFA. Acute oral rat study on CG. (2–20–57).
152.
152. CTFA. (November 1, 1977). Submission of unpublished data by CTFA. Acute oral rat study on CG. (2–20–69).
153.
153. CTFA. (April 23, 1978). Submission of unpublished data by CTFA. Acute oral rat study on CG. (2–20–65).
154.
154. CONSUMER PRODUCT TESTING. (August 28, 1979). Acute oral rat study on CG. (2–20–16).
155.
155. CTFA. (October 6, 1978). Submission of unpublished data by CTFA. Oral Toxicity, dermal, ocular, and mucous membrane irritation tests on CG. (2–20–3).
156.
156. Usmanov, K.U., Nadzhimutdinov, S., Bruevich, G.Y., Khakimov, Z.Z., and Komarin, A.S. (1982). Relation of carboxymethyl cellulose toxicity to its fractional composition, molecular weight and chemical compostion. Khim.-Farm. Zh.16(8), 974–8.
157.
157. Lautsch, E., et al. (1958). Artherosclerosis in rabbits after intravenous injection of colloidal solutions. Arch. Pathol.65, 40.
161. CTFA. (December 30, 1974). Submission of unpublished data by CTFA. Rat, mouse, and guinea pig acute dust inhalation study on HEC. (2–20–50).
162.
162. CTFA. (April 11, 1977). Submission of unpublished data by CTFA. Acute dermal toxicity study in rabbits on HPC. (2–20–27).
163.
163. CTFA. (January 9, 1975). Submission of unpublished data by CTFA. Rabbit eye irritation study on HEC. (2–20–43).
164.
164. CTFA. (January 9, 1975). Submission of unpublished data by CTFA. Rabbit eye irritation study on HEC. (2–20–44).
165.
165. Laillier, J., Plazonnet, B., Le Douarec, J.C., and Gonin, M.J. (1975, 1976). Evaluation of ocular irritation in the rabbit: Development of an objective method of studying eye irritation. Proc. Eur. Soc. Toxicol., Vol 17, ISS Predict. Chronic Toxic. Short Term Stud., Proc. Meet., pp. 336–50.
166.
166. CTFA. (September 25, 1962). Submission of unpublished data by CTFA. Rabbit ocular irritation study on HPC. (2–20–46).
167.
167. Gelatt, K.N., Gum, G.G., Williams, L.W., and Peiffer, Jr., R.L. (May 1979). Evaluation of a soluble sustained-release ophthalmic delivery unit in the dog. Am. J. Vet. Res.40(5), 702–4.
168.
168. CTFA. (May 1978). Submission of unpublished data by CTFA. Ocular irritation study in rabbits on HPMC. (2–20–86).
169.
169. CTFA. (November 7, 1974). Submission of unpublished data by CTFA. Ocular irritation study in rabbits on CG. (2–20–38).
170.
170. CTFA. (December 24, 1974). Submission of unpublished data by CTFA. Ocular irritation study in rabbits on CG. (2–20–39).
171.
171. CTFA. (February 11, 1980). Submission of unpublished data by CTFA. Ocular irritation in rabbits on CG. (2–20–58).
172.
172. CTFA. (November 1, 1977). Submission of unpublished data by CTFA. Ocular irritation study in rabbits on CG. (2–20–70).
173.
173. CTFA. (April 23, 1978). Submission of unpublished data by CTFA. Ocular irritation study in rabbits on CG. (2–20–66).
174.
174. FOOD AND DRUG RESEARCH LABORATORIES (FDRL). (April 5, 1979). Ocular irritation test in rabbits on CG. (2–20–19).
175.
175. CTFA. (November 1971). Submission of unpublished data by CTFA. Ocular irritation study in rabbits on CMC. (2–20–82).
176.
176. MINNESOTA MINING AND MFG. CO. (April 5, 1980). Nonirritating composition for prophylactic treatment of mastitis. Indian Patent No. 147552.
177.
177. CTFA. (April 6, 1979). Submission of unpublished data by CTFA. Skin irritation test in rabbits on HPMC. (2–20–23).
178.
178. CTFA. (May 1978). Submission of unpublished data by CTFA. Dermal irritation and toxicity test in rabbits on HPMC. (2–20–88).
179.
179. CTFA. (September 1972). Submission of unpublished data by CTFA. Dermal irritation study in rabbits on HPMC. (2–20–105).
180.
180. CTFA. (February 11, 1980). Submission of unpublished data by CTFA. Skin irritation test in rabbits on CG. (2–20–59).
181.
181. CTFA. (November 7, 1977). Submission of unpublished data by CTFA. SIPT in rabbits on CG. (2–20–71).
182.
182. CTFA. (April 23, 1978). Submission of unpublished data by CTFA. SIPT in rabbits on CG. (2–20–67).
183.
183. CTFA. (October 1971). Submission of unpublished data by CTFA. RIPT in rabbits on CMC. (2–20–84).
184.
184. CTFA. (March 6, 1961). Submission of unpublished data by CTFA. Chronic oral rat study on HEC. (2–20–51).
185.
185. CTFA. (August 23, 1963). Submission of unpublished data by CTFA. Subchronic oral rat study on HPC. (2–20–49).
186.
186. McCollister, S.B., Kociba, R.J., and McCollister, D.D. (1973). Dietary feeding studies of methylcellulose and hydroxypropylmethylcellulose in rats and dogs. Food Cosmet. Toxicol.11(6), 943–53.
187.
187. Schwetz, B.A., Humiston, C.G., Kociba, R.J., and Jersey, G.C. (1976). Results of subchronic toxicity studies on hydrochloric acid-tailored hydroxypropyl methylcellulose in rats and dogs. Polym. Prepr. Am. Chem. Soc. Div. Polym. Chem.17(1), 6–11.
188.
188. Hueper, W.C. (1946). Experimental studies in cardiovascular pathology. XII. Atheromatosis in dogs following repeated intravenous injections of solutions of Hydroxyethylcellulose. Arch. Pathol.41, 130–8.
189.
189. CTFA. (May 28, 1981). Submission of unpublished data by CTFA. Subchronic dermal toxicity study in rats on CG. (2–20–55).
190.
190. CTFA. (April 18, 1978). Submission of unpublished data by CTFA. Subchronic dermal toxicity study in rats on CG. (2–20–62).
191.
191. CTFA. (December 10, 1951). Submission of unpublished data by CTFA. Subchronic oral dog study on CG. (2–20–34).
192.
192. CTFA. (August 24, 1947). Submission of unpublished data by CTFA. Chronic oral guinea pig study on CG. (2–20–31).
193.
193. CTFA. (January 24, 1947). Submission of unpublished data by CTFA. Chronic oral rat study on CG. (2–20–33).
194.
194. CTFA. (December 5, 1980). Submission of unpublished data by CTFA. Guinea pig maximization test on HPMC. (2–20–28).
195.
195. CTFA. (May 1978). Submission of unpublished data by CTFA. Skin sensitization test in guinea pigs on HPMC. (2–20–89).
196.
196. CTFA. (April 20, 1979). Submission of unpublished data by CTFA. Rabbit phototoxicity study on HEC. (2–20–78).
197.
197. FDRL. (May 21, 1979). Primary dermal phototoxic irritation study in rabbits on CG. (2–20–17).
198.
198. Guettner, J., Klaus, S., and Heinecke, H. (1981). Embryotoxicity of intraperitoneally administered hydroxyethylcellulose in mice. Anat. Anz.149(3), 282–5.
199.
199. Kitagawa, H., Sato, T., Saito, H., Kato, M., Makita, T., and Hashimoto, Y. (1978). Teratological study of Hydroxypropylcellulose of low substitution (L-HPC) in rabbits. Oyo Yakuri16(2), 259–69.
200.
200. Kitagawa, H., Sato, T., Saito, H., Kato, M., Makita, T., and Hashimoto, Y. (1978). Teratological study of hydroxypropylcellulose of low substitution (L-HPC) in rats. Oyo Yakuri16(2), 271–98.
201.
201. CANNON LABS. (1975). Investigation of teratogenic and toxic potential of methocel in mice. Reading, PA. Prepared for the FDA, GRAS Review Branch, Washington, DC. NTIS Document No. PB-264 256.
202.
202. CANNON LABS. (1977). Investigation of teratogenic and toxic potential of methocel in mice. Reading, PA. Prepared for the FDA, GRAS Review Branch, Washington, DC. NTIS Document No. PB-262 117.
203.
203. Horvath, C., Szonyi, L., and Mold, K. (1976). Preventive effect of riboflavin and ATP on the teratogenic effects of the phenothiazine derivative T-82. Teratology14, 167–70.
204.
204. Robertson, R.T., Allen, H.L., and Bokelman, D.L. (1979). Aspirin: Teratogenic evaluation in the dog. Teratology20, 313–20.
205.
205. Fritz, H., Mueller, D., and Hess, R. (1976). Comparative study of the teratogenicity of phenobarbitone, diphenylhydantoin and carbamazepine in mice. Toxicology6, 323–30.
206.
206. Miller, R.P., and Becker, B.A. (1973). Teratogenicity of diazepam metabolites in Swiss-Webster mice. Toxicol. Appl. Pharmacol.25, 453.
207.
207. Sullivan, F.M., and McElhatton, P.R. (1977). Comparison of the teratogenic activity of the antiepileptic drugs carbamazepine, clonazepam, ethosuximide, phenobarbital, phenytoin and primidone in mice. Toxicol. Appl. Pharmacol.40, 365–78.
208.
208. Blevins, R.D., and Taylor, D.E. (1982). Mutagenicity screening of twenty-five cosmeticingredients with the Salmonella/microsome test. J. Environ. Sci. Health [Part A]A17(2), 217–39.
209.
209. LITTON BIONETICS. (1974). Mutagenic evaluation of compound FDA 71–51. Methocel. Kensington, MD. Prepared for the FDA, Washington, DC. NTIS Document No. PB 245 465.
210.
210. Kawachi, T., Yahagi, T., Kada, T., Tazima, Y., Ishidate, M., Sasaki, M., and Sugiyama, T. (1980). Cooperative program on short-term assays for carcinogenicity in Japan. IARC (Int. Agency Res. Cancer) Sci. Publ.27, 323–30.
211.
211. Sugimura, T., Sato, S., Nagao, M., Yahagi, T., Matsushima, T., Seino, Y., Takeuchi, M., and Kawachi, T. (1976). Overlapping of Carcinogens and Mutagens. Fundam. Cancer Prev., 6th Symp. Princess Takamatsu Cancer Res. Fund (1975), pp. 191–215.
212.
212. NATIONAL CANCER INSTITUTE (NCI). (1980). Bioassay of selenium sulfide (gavage) for possible carcinogenicity. Bethesda, MD. NCI Carcinogenesis Technical Report Series, No. 194, NTP No. 80–17, PB 82–164955.
213.
213. WORLD HEALTH ORGANIZATION (WHO). (1974). Modified cellulose toxicological studies. WHO Food Additive Series 5, Geneva, Switzerland.
214.
214. Chin, C., Hsieh, H., and Yu, C. (1980). Preparation of long-acting eye drops. Yao Hsueh Tung Pao15(6), 13–4.
215.
215. CTFA. (March 23, 1962). Submission of unpublished data by CTFA. Clinical Repeat Insult Patch Test (RIPT) on HEC. (2–20–52).
216.
216. Faucher, J.A., Goddard, E.D., and Harriman, R.B. (1977). Protection of the skin by a cationic cellulose polymer. Cosmet. Toiletries92, 39–44.
217.
217. CTFA. (Septembers, 1962). Submission of unpublished data by CTFA. Clinical RIPT on HPC. (2–20–48).
218.
218. RESEARCH TESTING LABORATORIES (RTL). (October 11, 1979). Clinical controlled use-study on MC. (2–20–54).
219.
219. FDRL. (March 12, 1974). Clinical RIPT on MC. (2–20–92).
220.
220. HILL TOP RESEARCH (HTR). (March 29, 1971). Clinical RIPT on HPMC. (2–20–91).
221.
221. CTFA. (November 13, 1952). Submission of unpublished data by CTFA. Clinical patch test on CG. (2–20–32).
222.
222. Bergman, B., Lowhagen, G.B., and Mobacken, H. (1982). Irritant skin reactions to urostomal adhesives. Urol. Res.10(3), 153–5.
223.
223. CTFA. (May 1978). Submission of unpublished data by CTFA. Clinical RIPT on HEC. (2–20–90).
224.
224. RTL. (April 30, 1980). Clinical RIPT on HEC (2–20–73).
225.
225. RTL (April 30, 1980). Clinical RIPT on HEC (2–20–76).
226.
226. CTFA. (October 17, 1980). Submission of unpublished data by CTFA. Clinical RIPT on HEC (2–20–77).
253. CTFA. (May 1974). Submission of unpublished data by CTFA. Clinical modified maximization test with UV exposure on CMC. (2–20–83).
254.
254. Oram, C., and Beck, J. (1981). The tampon: Investigated and challenged. Women Health6(3–4), 105–22.
255.
255. Tierno, P.M. Jr., Hanna, B.A., and Davies, M.B. (1983). Growth of toxic-shock-syndrome strain of Staphylococcus aureus after enzymic degradation of Rely tampon component. Lancet1(8325), 615–8.
256.
256. Masuda, H., Sumiyoshi, Y., Shiojima, Y., Suda, T., Kikyo, T., Iwata, M., Fujiyama, N., Machida, Y., and Nagai, K. (October 15, 1981). Local therapy of carcinoma of the uterine cervix: Part I. Cancer.48(8), 189–906.
257.
257. Clayton, G.D., and Clayton, F.E. (eds.). (1981). Patty's Industrial Hygiene and Toxicology, 3rd ed.New York, NY: Wiley, Vol. 2A.
